Oncolys BioPharma, Inc.
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Oncolys BioPharma, Inc.
Asia Deal Watch: Antibody-Drug Conjugates Reign With Alliances Involving Celltrion, Miracogen & WuXi Biologics
Celltrion and iProgen will co-develop ADC candidates, Miracogen and Synaffix sign a technology license after a successful research collaboration, and WuXi will provide clinical trial material to NBE Therapeutics.
Merck could pay up to $167m to try a new epigenetic target, which would build on its existing HDAC inhibitor. Meanwhile, Celgene buys epigenetics-focused Acetylon, which will spin out new company Regenacy to work with its lead HDAC6 inhibitor outside of oncology.
Acucela, a US venture specializing in ophthalmic disorders, is planning to raise up to $125m in an initial public offering in Tokyo to support the development and commercialization of its pipeline.
The Japanese venture Oncolys BioPharma has floated on the Mothers high-tech market of the Tokyo Stock Exchange, raising around JPY4.7bn ($46m) to develop its pipeline of drugs and diagnostics for cancer and serious infections.
- Consulting Services
- Specialty Pharmaceuticals
In Vitro Diagnostics
- Molecular Diagnostics & Genetic Testing
- Gene Therapy, Cell Therapy
- Large Molecule
- Other Names / Subsidiaries
- Oncolys USA Inc
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.